Elevated MICs of susceptible antipseudomonal cephalosporins in non-carbapenemase-producing, carbapenem-resistant pseudomonas aeruginosa: Implications for dose optimization

Autores organización
Autores
- Gill C.M.
- Aktas E.
- Alfouzan W.
- Bourassa L.
- Brink A.
- Burnham C.-A.D.
- Canton R.
- Carmeli Y.
- Falcone M.
- Kiffer C.
- Marchese A.
- Martinez O.
- Pournaras S.
- Seifert H.
- Thabit A.K.
- Westblade L.F.
- Nicolau D.P.
- Wille J.
- Rezende T.T.F.
- Cekin Z.
- Malkocoglu G.
- Gijón D.
- Tarakmeh L.A.
- Chu C.Y.
- Opperman C.J.
- Tootla H.D.
- Moodley C.
- Coetzee J.
- Vourli S.
- Dimopoulos G.
- Attallah D.M.
- Tiseo G.
- Leonildi A.
- Giordano C.
- Barnini S.
- Menichetti F.
- Di Pilato V.
- Codda G.
- Vena A.
- Giacobbe D.R.
- Satlin M.
- Curtis L.
- Fang F.
- Thomson G.
- Thomson K.
Grupos de investigación
Resumen
The present study evaluated the in vitro potency of ceftazidime and cefepime among carbapenem-resistant Pseudomonas aeruginosa isolates collected as part of a global surveillance program and assessed the pharmacodynamic implications using previously published population pharmacokinetics. When susceptible, MICs resulted at the high end of distribution for both ceftazidime and cefepime, thus 6 g/day was required to achieve optimal pharmacodynamic profiles. These findings should be considered in the clinic and for the application of CLSI susceptibility breakpoints. © 2021 American Society for Microbiology.
Datos de la publicación
- ISSN/ISSNe:
- 0066-4804, 1098-6596
- Tipo:
- Article
- Páginas:
- -
- DOI:
- 10.1128/AAC.01204-21
- PubMed:
- 34398670
- Enlace a otro recurso:
- www.scopus.com
Antimicrobial Agents And Chemotherapy American Society for Microbiology
Citas Recibidas en Scopus: 7
Documentos
- No hay documentos
Filiaciones
Keywords
- Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; cefepime; ceftazidime; antiinfective agent; azabicyclo derivative; carbapenem derivative; ceftazidime; cephalosporin derivative; antibiotic sensitivity; Article; bacterium isolate; carbapenem resistant Pseudomonas aeruginosa; clinical laboratory standard; controlled study; dose calculation; drug potency; in vitro study; maximum permissible dose; MIC50; MIC90; Monte Carlo method; nonhuman; process optimization; human; microbial sensitivity test; Pseudomonas aeruginosa; Pseudomonas infection
Proyectos asociados
Determinación de la huella transcipcional de mastocitos aislados de pulpa dental humana sana y con signos clínicos de inflamación
Investigador Principal: MARIA ROSA BUENAHORA TOBAR
PCI-2019-10765 . 2020
EFECTO DEL EXTRACTO DE Trametes versicolor SOBRE EL FENOTIPO Y LA FUNCIÓN DE CÉLULAS DENDRÍTICAS HUMANAS CONDICIONADAS CON MEDIOS DE CÉLULAS DE CARCINOMA ORAL
Investigador Principal: ANDRES FELIPE CARDONA MENDOZA
PCI-2019-10805 . 2020
Creating a Latin America network for clinical training and support of pharmacists and hospital financial decision makers involved in ASPs
Investigador Principal: MARIA VIRGINIA VILLEGAS BOTERO
UEB-2020-585 . 2020
Caracterización Molecular de Aislamientos Resistentes a Ceftazidime Avibactam en Enterobacterales y Pseudomonas aeruginosa recolectados en cinco Países de América Latina. Molecular mechanisms leading to ceftazidime-avibactam resistance in Enterobacterales and Pseudomonas aeruginosa collected from five Latin American countries
Investigador Principal: MARIA VIRGINIA VILLEGAS BOTERO
UEB-2020-586 . 2020